GeneDx Holdings (WGS) Research & Development: 2020-2025
Historic Research & Development for GeneDx Holdings (WGS) over the last 6 years, with Sep 2025 value amounting to $19.8 million.
- GeneDx Holdings' Research & Development rose 69.99% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.1 million, marking a year-over-year increase of 27.36%. This contributed to the annual value of $45.7 million for FY2024, which is 21.53% down from last year.
- Per GeneDx Holdings' latest filing, its Research & Development stood at $19.8 million for Q3 2025, which was up 31.50% from $15.1 million recorded in Q2 2025.
- In the past 5 years, GeneDx Holdings' Research & Development ranged from a high of $53.1 million in Q1 2021 and a low of $10.9 million during Q2 2024.
- Over the past 3 years, GeneDx Holdings' median Research & Development value was $12.6 million (recorded in 2025), while the average stood at $13.8 million.
- The largest annual percentage gain for GeneDx Holdings' Research & Development in the last 5 years was 127.31% (2022), contrasted with its biggest fall of 59.88% (2022).
- Quarterly analysis of 5 years shows GeneDx Holdings' Research & Development stood at $22.2 million in 2021, then increased by 9.53% to $24.4 million in 2022, then tumbled by 49.73% to $12.2 million in 2023, then dropped by 5.39% to $11.6 million in 2024, then skyrocketed by 69.99% to $19.8 million in 2025.
- Its Research & Development stands at $19.8 million for Q3 2025, versus $15.1 million for Q2 2025 and $12.6 million for Q1 2025.